Antiangiogenic treatments of advanced non-small cell lung cancer

作者：Manegold Christian^*

来源：Targeted Oncology, 2008, 3(3): 187-196.

DOI：10.1007/s11523-008-0087-4

• Non-small cell lung cancer
• Bevacizumab
• Angiogenesis inhibitors
• Vascular endothelial growth factor

Over the past decades, chemotherapy regimens have only offered moderate improvements in survival to patients with advanced or metastatic non-small cell lung cancer (NSCLC). The advent of targeted therapies, which selectively inhibit tumor-specific biological pathways, heralds a new era for cancer care. Targeting vascular endothelial growth factor (VEGF)-a potent regulator of tumor angiogenesis-is now considered to be a rational anticancer strategy. Bevacizumab is a monoclonal antibody that specifically inhibits VEGF. In large, randomized, phase III trials, bevacizumab-based therapy demonstrated significant improvements in patient outcomes coupled with a favorable safety profile in non-squamous NSCLC. The results of the numerous ongoing studies concerning the use of bevacizumab in other histological types and in previously ineligible patient populations, its optimal combination with other targeted therapies, and the potential of bevacizumab in earlier-stage disease, are eagerly awaited.

• 出版日期2008-7